骨保护素及骨硬化蛋白水平与维持透析患者冠状动脉钙化程度的关系

doi:10.3969/j.issn.1006-6233.2022.05.028

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1244 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的:探讨维持透析患者血清骨保护素(OPG)和骨硬化蛋白(SO)水平与冠状动脉钙化(coronary artery calcification,CAC)的发生及其积分(CAC score,CACS)之间的关联。方法:选取2018年11月至2020年11月于我科行维持透析治疗的183例患者作研究对象,将CACS≤100分者纳入低分组(80例),>100分者纳入高分组(103例)。收集患者临床资料,检测血清OPG和SO水平。行单因素分析及多元线性回归分析维持透析患者发生CAC的独立危险因素,分析OPG和SO水平与CACS评分相关性。结果:高分组透析龄和糖尿病例数均高于低分组(P<0.05);高分组血清CRP、OPG和SO水平均高于低分组(P<0.05);OPG水平(r=0.871,P=0.000)、SO水平(r=0.772,P=0.000)均与CACS评分呈正相关;透析龄、OPG、SO和CRP水平均为维持透析患者发生冠状动脉钙化的独立危险因素(P<0.05)。结论:维持透析患者血清OPG和SO水平与CAC发生有关,二者未来可能成为预测CAC的可靠手段。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	邓真真
	陈铖
	熊淑珍
	周新华

关键词 ：透析, 骨保护素, 骨硬化蛋白, 冠状动脉钙化

Abstract：Objective: To explore the correlation between serum osteoprotegerin(OPG)or sclerostin(SO)level and coronary artery calcification(CAC)occurrence as well as related score(CAC score,CACS)in maintenance dialysis patients. Methods: 183 patients who received maintenance dialysis treatment in our department from November 2018 to November 2020 were selected as the research objects. Those with CACS ≤ 100 were included in the low group (80 cases) and those with CACS > 100 were included in the high group (103 cases). The clinical data of patients were collected and the levels of serum OPG and so were detected. Univariate analysis and multiple linear regression were used to analyze the independent risk factors of CAC in maintenance dialysis patients, and the correlation between OPG and so levels and CACS score was analyzed. Results: The age of dialysis and the number of diabetes in high group were higher than those in low group (P<0.05). The levels of serum CRP, OPG and so in high group were higher than those in low group (P<0.05); OPG level (r = 0.871, P = 0.000) and so level (r = 0.772, P = 0.000) were positively correlated with CACS score; Dialysis age, OPG, so and CRP levels were independent risk factors for coronary artery calcification in maintenance dialysis patients (P<0.05). Conclusion: The levels of serum OPG and so in maintenance dialysis patients are related to the occurrence of CAC. They may become a reliable means to predict CAC in the future.

Key words： Dialysis OPG SO CAC

基金资助:江西省卫生健康委科技计划,(编号:20202011)

引用本文:

邓真真, 陈铖, 熊淑珍, 周新华. 骨保护素及骨硬化蛋白水平与维持透析患者冠状动脉钙化程度的关系[J]. 河北医学, 2022, 28(5): 834-838.
DENG Zhenzhen, CHEN Cheng, XIONG Shuzhen, et al. Relationship between the Levels of Osteoprotegerin and Osteosclerosis Protein and the Degree of Coronary Artery Calcification in Maintenance Dialysis Patients. HeBei Med, 2022, 28(5): 834-838.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2022.05.028 或 http://www.hbyxzzs.cn/CN/Y2022/V28/I5/834

[1] Bundy JD,Cai X,Scialla JJ,et al.Serum calcification propensity and coronary artery calcification among patients with CKD:the CRIC (chronic renal insufficiency cohort) study[J].Am Kidney Dis,2019,73(6):806~814.
[2] Bundy JD,Chen J,Yang W,et al.Risk factors for progression of coronary artery calcification in patients with chronic kidney disease:The CRIC study[J].Atherosclerosis,2018,271(4):53~60.
[3] Dai L,Plunde O,Qureshi AR,et al.Aortic valve calcium associates with all-cause mortality independent of coronary artery calcium and inflammation in patients with end-stage renal disease[J].Clin Med,2020,9(2):607.
[4] Kalousova M,Dusilova-Sulkova S,Kubena AA,et al.Sclerostin levels predict cardiovascular mortality in long-term hemodialysis patients:a prospective observational cohort study[J].Physiol Res,2019,68(4):547~558.
[5] Bundy JD,Chen J,Yang W,et al.Risk factors for progression of coronary artery calcification in patients with chronic kidney disease:The CRIC study[J].Atherosclerosis,2018,271(5):53~60.
[6] Fujii H,Kono K,Nishi S.Characteristics of coronary artery disease in chronic kidney disease[J].Clin Exp Nephrol,2019,23(6):725~732.
[7] Guven S,Gokce I,Cicek N,et al.Sclerostin and osteoprotegerin:new markers of chronic kidney disease mediated mineral and bone disease in children[J].Pediatr Endocrinol Metab,2020,33(11):1383~1390.
[8] Bernardi S, Toffoli B, Bossi F, et al.Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients[J].BMC Nephrol, 2017,18(1):219.
[9] Marques GL,Hayashi S,Bjallmark A,et al.Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3-5[J].Sci Rep,2021,11(1):2473.
[10] Zou Y,Yang M,Wang J,et al.Association of sclerostin with cardiovascular events and mortality in dialysis patients[J].Ren Fail,2020,42(1):282~288.
[11] 戴璇,李月红,姜埃利,等.骨硬化蛋白在慢性肾脏病发病及血管钙化中作用的研究进展[J].山东医药,2019,59(32):96~99.
[12] Kundakci Gelir G,Sengul S,Nergizoglu G,et al.Is sclerostin level associated with cardiovascular diseases in hemodialysis patients[J].Blood Purif,2018,46(2):118~125.
[13] Frysz M,Gergei I,Scharnagl H,et al.Circulating sclerostin levels are positively related to coronary artery disease severity and related risk factors[J].Bone Miner Res,2022,37(2):273~284.